Roles of tumor necrosis factor p55 and p75 receptors in TNF-α-induced vascular permeability

American Journal of Physiology - Cell Physiology

Volumn 281, Issue 4 50-4, 2001, Pages

  Ferrero, Elisabetta ^a   Zocchi, Maria Raffaella ^a   Magni, Elena ^a   Panzeri, Maria Carla ^a   Curnis, Flavio ^a   Rugarli, Claudio ^a   Ferrero, Maria Elena ^b   Corti, Angelo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cytoskeleton; Endothelium; Receptor

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BLOOD VESSEL PERMEABILITY; CELL ISOLATION; CYTOSKELETON; HUMAN; HUMAN CELL; LIVER BLOOD FLOW; MONOLAYER CULTURE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0034785749     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.2001.281.4.c1173     Document Type: Article

References (43)

1. Mode of interaction between tumor necrosis factor α and a monoclonal antibody expressing a recurrent idiotype
2. Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity
3. Isolation of intact liver cells
4. Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins
5. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies
6. Identification of an epitope of tumor necrosis factor (TNF)-receptor type 1 (p55) recognized by a TNF-α-antagonist monoclonal antibody
7. Tumor necrosis factor (TNF) α quantification by ELISA and bioassay: Effects of TNF α-soluble TNF receptor (p55) complex dissociation during assay incubations
8. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
9. Antibodies to a soluble form of the tumor necrosis factor (TNF) receptor have TNF-like activity
10. Characterization of binding and biological effects of monoclonal antibodies against a human tumor necrosis factor receptor
11. Nitric oxide mediates tumor necrosis factor-α cytotoxicity in endothelial cells
12. The platelet endothelial cell adhesion molecule-1 (PECAM1) contributes to endothelial barrier function
13. Tumor necrosis factor α-induced vascular leakage involves PECAM1 phosphorylation
14. Biologic therapy with TNF: Preclinical studies
15. Biologic therapy with TNF: Systemic administration and isolation-perfusion
16. TNF-α induces endothelial cell F-actin depolymerization, new actin synthesis, and barrier dysfunction
17. Tumor necrosis factor-α augments pulmonary arterial transendothelial albumin flux in vitro
18. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells
19. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF
20. Human tumor necrosis factor α (TNF α) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors
21. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55
22. Involvement of the 55- and 75-kDa tumor necrosis factor receptors in the generation of lymphokine-activated killer cell activity and proliferation of natural killer cells
23. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1
24. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas
25. Modulation of endothelial cell hemostatic properties by tumor necrosis factor
26. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor
27. Human tumor necrosis factor: Precursor, structure, expression and homology to lymphotoxin
28. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
29. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells
30. Activation of cultured human endothelial cells by recombinant lymphotoxin: Comparison with tumor necrosis factor and interleukin 1 species
31. Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor α
32. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration
33. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
34. The two different receptors for tumor necrosis factor mediate distinct cellular responses
35. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses
36. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
37. Human tumor necrosis factor mutants with preferential binding to and activity on either the R55 or R75 receptor
38. A human tumor necrosis factor (TNF) α mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon
39. Two tumor necrosis factor receptors: Structure and function
40. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma
41. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: Requirement of the TNF receptor-associated factor-2 binding site
42. A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon
43. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life